EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome

Marko P Ravić iD, Ivan M Srejović iD, Marijana M Andjić, Maja D Murić iD, Jasmina Z Sretenović iD, Nevena S Jeremić iD, Isidora M Milosavljević iD, Miona Lj Vuletić, Nemanja N Murić iD, Katarina R Ravić, Sergey B Bolevich iD, Svetlana P Sergeeva und 4 weitere

Medical Sciences · 2026

DOI: 10.3390/medsci14050590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, 2026. Verfasst von Marko P Ravić und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Metabolic Syndrome, Oxidative Stress, Liraglutide, Glucagon-Like Peptides. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medical Sciences, University of Kragujevac, Ministry of Science, Technical Development, and Innovation of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metabolic syndrome (MetS) increases susceptibility to myocardial ischemia/reperfusion (I/R) injury through metabolic disturbance, hypertension, and oxidative stress. This study aimed to compare the effects of liraglutide and semaglutide on post-ischemic cardiac function, oxidative stress, and histomorphological changes in rats with MetS.

Methods

MetS was induced in male Wistar rats by a high-fat diet followed by low-dose streptozotocin. After confirmation of MetS, animals were treated with saline, liraglutide, or semaglutide for 6 weeks. Blood pressure, glycemia, oral glucose tolerance, and lipid profile were assessed during the protocol. In vivo cardiac function was evaluated by echocardiography, whereas ex vivo I/R injury was induced using the Langendorff technique. Cardiodynamic parameters, coronary flow, oxidative stress markers, and histological changes in the heart, liver, and pancreas were analyzed.

Results

Both liraglutide and semaglutide improved the cardiometabolic profile of MetS rats, with semaglutide showing a more evident effect on body weight control. In the Langendorff model, both treatments improved post-ischemic recovery of myocardial contractility and relaxation during reperfusion. Treated animals also showed a more favorable oxidative stress profile, particularly lower superoxide anion levels and enhanced antioxidant defense. Histologically, both agents attenuated myocardial hypertrophy and collagen deposition, improved hepatic architecture by reducing inflammatory changes, and preserved pancreatic structure with less lipid accumulation and tissue injury.

Conclusions

Liraglutide and semaglutide exerted significant cardioprotective and tissue-protective effects in experimental MetS complicated by myocardial I/R injury. These findings support their potential in limiting post-ischemic cardiac dysfunction and multiorgan damage in metabolically compromised conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeOxidative StressLiraglutideGlucagon-Like PeptidesAnimalsSemaglutideMaleRatsDisease Models, AnimalRats, WistarMyocardial Reperfusion InjuryMyocardium

Stichwörter der Autor:innen

cardiac remodelingcardioprotectionliraglutidemetabolic syndromemyocardial ischemia/reperfusionoxidative stresssemaglutide

Substanzen

SemaglutideLiraglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
  • Center of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
  • Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
  • Department of Pharmacology, First Moscow State Medical University I.M. Sechenov, Trubetskaya Street 8, Str. 2, Moscow 119991, Russia.
  • A.P. Neyubin Institute of Pharmacy, First Moscow State Medical University I.M. Sechenov, Moscow 119435, Russia.
  • Department of Dentistry, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.

ORCID-Profile: Marko P Ravić, Ivan M Srejović, Maja D Murić, Jasmina Z Sretenović, Nevena S Jeremić, Isidora M Milosavljević, Nemanja N Murić, Sergey B Bolevich, Alexander A Gorbunov, Vladimir Lj Jakovljević, Jovana N Novaković

Förderung

  • Faculty of Medical Sciences, University of Kragujevac
  • Ministry of Science, Technical Development, and Innovation of the Republic of Serbia

Zitieren

APA

Ravić, M. P., Srejović, I. M., Andjić, M. M., Murić, M. D., Sretenović, J. Z., Jeremić, N. S., Milosavljević, I. M., Vuletić, M. L., Murić, N. N., Ravić, K. R., Bolevich, S. B., Sergeeva, S. P., Gorbunov, A. A., Bolevich, S. S., Jakovljević, V. L., & Novaković, J. N. (2026). Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome. Medical Sciences. https://doi.org/10.3390/medsci14050590

Vancouver

Ravić MP, Srejović IM, Andjić MM, Murić MD, Sretenović JZ, Jeremić NS, et al. Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome. Medical Sciences. 2026. doi:10.3390/medsci14050590

BibTeX
@article{Ravi2026,
  author = {Ravić, Marko P and Srejović, Ivan M and Andjić, Marijana M and Murić, Maja D and Sretenović, Jasmina Z and Jeremić, Nevena S and Milosavljević, Isidora M and Vuletić, Miona Lj and Murić, Nemanja N and Ravić, Katarina R and Bolevich, Sergey B and Sergeeva, Svetlana P and Gorbunov, Alexander A and Bolevich, Stefani S and Jakovljević, Vladimir Lj and Novaković, Jovana N},
  title = {Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14050590}
}
Kostenlos starten →